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Background: Since betaine is an osmolyte and methyl donor, and abnormal betaine loss is common in diabetes
mellitus (>20% patients), we investigated the relationship between betaine and the post-methionine load rise in
homocysteine, in diabetes and control subjects. The post-methionine load test is reported to be both an
independent vascular risk factor and a measure of betaine sufficiency.
Methods: Patients with type 2 diabetes (n= 34) and control subjects (n= 17) were recruited. We measured baseline
fasting plasma and 4-hour post-methionine load (L-methionine, 0.1 mg/kg body weight) concentrations of
homocysteine, betaine, and the betaine metabolite N,N-dimethylglycine. Baseline urine excretions of betaine,
dimethylglycine and glucose were measured on morning urine samples as the ratio to urine creatinine. Statistical
determinants of the post-methionine load increase in homocysteine were identified in multiple linear regression
models.
Results: Plasma betaine concentrations and urinary betaine excretions were significantly (p< 0.001) more variable in
the subjects with diabetes compared with the controls. Dimethylglycine excretion (p= 0.00014) and plasma
dimethylglycine concentrations (p= 0.039) were also more variable. In diabetes, plasma betaine was a significant
negative determinant (p< 0.001) of the post-methionine load increase in homocysteine. However, it was not
conclusive that this was different from the relationship in the controls. In the patients with diabetes, a strong
relationship was found between urinary betaine excretion and urinary glucose excretion (but not with plasma
glucose).
Conclusions: Both high and low plasma betaine concentrations, and high and low urinary betaine excretions, are
more prevalent in diabetes. The availability of betaine affects the response in the methionine load test. The benefits
of increasing betaine intake should be investigated.
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Betaine (“glycine betaine”, “trimethylglycine” or “TMG”)
is a major osmolyte, accumulated in tissues for cell-
volume regulation [1-3], and this tissue store is also a
reservoir of methyl groups. Betaine is essential for life,
and is obtained either from the diet [4,5] or endogen-
ously by the mitochondrial oxidation of choline [6].
Therefore it is of interest that more than 20% of patients
with diabetes mellitus excrete abnormal amounts of
betaine in their urine [7,8], and it is worth considering
the metabolic consequences of this loss. Betaine catabol-
ism is mediated by betaine-homocysteine methyltransfer-
ase which is known to be regulated both by the supply of
methyl groups [9] and by osmotic stress [10,11].
Through this enzyme, betaine is a major determinant of
circulating homocysteine in mice [12], and in patients
with lipid disorders the urinary excretion of betaine is
the main factor affecting plasma homocysteine [13,14]. It
has been suggested that betaine deficiency is a common
feature of the metabolic syndrome [15,16], and may be
pathogenic. In a large cross-sectional study, low plasma
betaine concentrations were associated with an un-
favourable atherogenic risk profile. [17] and subjects with
lipid disorders who excreted high levels of betaine
appeared to have an increased incidence of vascular dis-
ease [18].
The methionine load test has been proposed as a
measure of betaine sufficiency [15,16,19], and the rise in
homocysteine in this test is an independent risk factor
for vascular disease [20,21]. We therefore compared the
responses of patients with type 2 diabetes and matched
control subjects in the methionine load test.
Methods
Methionine load test study
The study was approved by the Canterbury Ethics
Committee (New Zealand) and all subjects gave written
informed consent. Patients with Type 2 diabetes were
identified through the Canterbury retinal screening
programme database and invited to participate. Controls
were recruited by posting notices around the hospital cam-
pus. Thirty four patients (aged 51–75 yrs, 20 males) and
17 controls (aged 54–69 yrs, 10 male) were recruited. They
were asked to fast for 16 hours and to withhold morning
medications. Their height, weight, age, and medical history
were recorded. Venous blood was drawn into EDTA tubes
that were placed on ice immediately for determining fast-
ing plasma betaine and homocysteine concentrations and
a urine sample was collected. They were then given a me-
thionine load of 0.1 g/kg body weight of L-methionine dis-
solved in 100 ml fruit juice. They also ate a standard snack
consisting of a jam (jelly) sandwich to avoid hypoglycaemia.
They took no further food or fluid until their return 4 hours
later, when a second venous blood sample was collected.The betaine, dimethylglycine and homocysteine from the
pre- and post- methionine load blood samples were mea-
sured in the same analytical batches.
Analytical methods
Betaine and N,N-dimethylglycine were measured in
plasma and urine by high performance liquid chroma-
tography (HPLC) as their 2-naphthacyl derivatives
[22,23]. Plasma homocysteine was measured by fluores-
cence polarization on an Abbott IMX Analyzer (Abbott
Laboratories). Creatinine was measured in plasma and
urine using the Jaffé reaction on the fully automated
Abbott Aeroset Analyzer (Abbott Laboratories, USA).
Serum vitamin B12 and red blood cell (RBC) folate con-
centrations were measured by separate competitive
immunoassays on an automated Chemiluminescence
ACS:180 Analyzer (Chiron Diagnostics Corporation;
USA). Hemoglobin A1c was measured by the Diamat
fully automated glycosylated hemoglobin analyzer system
(Bio-Rad) and were expressed as a percentage of
hemoglobin.
Statistical methods
Urine betaine and N,N-dimethylglycine excretions were
positively skewed, and in the subjects with diabetes
plasma betaine, dimethylglycine, homocysteine and
serum vitamin B12 concentrations were also positively
skewed. Where the raw data was not normally distribu-
ted (Kolmogorov-Smirnov test) the data were log trans-
formed prior to conducting correlation and regression
analyses. Associations were evaluated as Pearson’s correl-
ation coefficient and from multiple linear regression
models. The regression models were based on the most
significant variables that consistently appeared in at least
12 best subsets regression models (not reported), and
only significant variables are included in the final models
presented. Statistical analyses and figure preparation
were carried out using SigmaPlot for Windows version
11.2 (Systat Software Inc).
Results
Characteristics of the groups
The subjects with diabetes were slightly older than the
control subjects (Table 1). Almost all subjects were folate
and vitamin B12 replete. The fasting blood glucose con-
centrations of the subjects with diabetes were, as
expected, higher than in the controls (Table 1), and the
hemoglobin A1c data shows that the subjects with dia-
betes had varied degrees of control.
Differences between subjects with and without diabetes
In this study, the medians of fasting plasma betaine and
N,N-dimethylglycine concentrations, fasting plasma total
homocysteine, the rise in homocysteine, and the
Table 1 Characteristics of subjects in methionine load test
study
N Median Full range
Females with diabetes:
Age (y) 14 67.5 60 – 74
Body Mass Index 14 27.0 17.1 - 37.6
Fasting plasma glucose (μmol/L) 14 7.4 5.5 - 10.2
Serum vitamin B12 (pmol/L) 14 337 215 – 587
Red cell folate (nmol/L) 14 677 508 – 964
Hemoglobin A1c (%) 14 7.75 6.7 - 9.8
Males with diabetes:
Age (y) 20 69 51 – 75
Body Mass Index 20 27.2 22.1 - 42.3
Fasting plasma glucose (μmol/L) 20 7.85 4.8 - 14.8
Serum vitamin B12 (pmol/L) 20 330.5 129 – 697
Red cell folate (nmol/L) 20 655.5 406 – 1046
Hemoglobin A1c (%) 20 7.4 5.3 - 9.0
Female control subjects:
Age (y) 7 63 55 – 69
Body Mass Index 7 28.7 24.9 - 33.5
Fasting plasma glucose (μmol/L) 7 4.5 3.9 - 5.8
Serum vitamin B12 (pmol/L) 7 357 302 – 580
Red cell folate (nmol/L) 7 840 546 – 1071
Male control subjects:
Age (y) 10 57 54 – 66
Body Mass Index 10 26.8 21.1 - 36.5
Fasting plasma glucose (μmol/L) 10 4.75 3.9 - 5.8
Serum vitamin B12 (pmol/L) 10 355.5 227 – 837
Red cell folate (nmol/L) 10 847 507 – 971
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significantly different between subjects with diabetes and
controls (Figure 1). The striking difference is the greater
variability of plasma betaine concentrations, and urine
betaine excretions (Figure 1), in the subjects with dia-
betes. A similarly increased variability is apparent with
N,N-dimethylglycine. The difference in variability was
less pronounced for fasting plasma homocysteine and
the rise in homocysteine after a methionine load
(Figure 1), and a trend for higher variability in the sub-
jects with diabetes was not significant in this study.
The post-methionine load plasma betaine and
homocysteine concentrations were also significantly
more variable in the subjects with diabetes (on log-
transformed data, p< 0.001 for betaine and p = 0.0016
for N,N-dimethylglycine), as was the post-methionine
change in plasma N,N-dimethylglycine (p = 0.013), but
not the post-methionine change in plasma betaine
(p = 0.7).Predictors of the post-methionine load increase in
homocysteine
In the subjects with diabetes, the statistically significant
(p< 0.05) predictors of the post-methionine load increase
in plasma homocysteine, identified by best subset regres-
sion, were fasting plasma homocysteine, either fasting or
post-methionine load betaine, and (in most models) serum
vitamin B12. Variables that did not enter any of 36 models
with p< 0.1 included age, body mass index, red blood cell
folate, hemoglobin A1c, plasma glucose concentrations,
plasma N,N-dimethylglycine concentration (either fasting
or post-methionine load), and the urinary excretions of
glucose, betaine and N,N-dimethylglycine. Log-trans-
formed variables were used where the raw data was not
normally distributed (Kolmogorov-Smirnov test). The
three strongest candidate predictors (all log-transformed)
were included in an explicit multiple linear regression
model (Figure 2) which confirmed that the fasting plasma
homocysteine was the strongest (positive) predictor, and
the post-methionine load plasma betaine concentration
was also a highly significant (p< 0.001) negative predictor.
The serum vitamin B12 concentration also a positive pre-
dictor (p=0.021). The model explained most of the vari-
ance in the post-methionine load increase in homocysteine
(r2 = 0.69). When the fasting plasma betaine concentration
was included in the model instead of the post-methionine
concentration, a similar result was obtained (r2 = 0.56) but
the fasting betaine concentration appears to be a weaker
negative predictor (p=0.013).
The best subsets models of the post-methionine load in-
crease in plasma homocysteine calculated on the control
subjects either showed no significant predictors, or the
fasting plasma homocysteine concentration appeared as a
sole significant predictor. The same three-factor explicit
multiple regression model was generated using the control
data (Figure 2); this was a poorer model than when the
subjects with diabetes were used (r2 = 0.32) and none of
the terms were significant.
Regression models were also estimated using all subject
data (combined controls and subjects with diabetes). In
the three variable linear regression model (r2 = 0.58) both
fasting homocysteine (positive) and post-methionine load
plasma betaine (negative) were significant predictors
(p< 0.001) but vitamin B12 was not significant (p = 0.077).
If diabetes (0 or 1) was included as a variable in best-sub-
sets regression models it was in no case significant. Age
also did not enter any of the models as a predictor.
Glucose, betaine and homocysteine
Betaine excretion positively correlated with glucose ex-
cretion (log transformed data; r=+0.47, p= 0.005, n= 34)
in patients with diabetes. Dimethylglycine excretion also
correlated with glucose excretion (log transformed data;


































































































































p = 0.00002 p = 0.00014
p = 0.0007 p = 0.039
p = 0.077 p = 0.146
Figure 1 Variability of betaine and homocysteine metabolites. Variablity in subjects with diabetes (n= 34) and control subjects (n= 17). DMG: N,
N-dimethylglycine. The p values are the significance of the differences between the variances of the subjects with and without diabetes, calculated
using log-transformed data. The change in homocysteine is the difference between the plasma homocysteine before and 4 h after a methionine load;
plasma betaine and homocysteine concentrations are fasting, before a methionine load.
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betaine excretion (r=+0.33, p=0.056, n=34); the
Spearman’s correlation coefficient was significant (rs=+0.37,
p=0.03). Neither fasting homocysteine, nor the post-me-
thionine load increase in homocysteine, correlated with ei-
ther plasma glucose or glucose excretion. Hemoglobin A1c
did not strongly correlate with betaine excretion, but therewas a significant positive correlation (r=+0.52, p=0.003,
n=30) between hemoglobin A1c and the post-methionine
load change in plasma dimethylglycine (measured as the
difference in log(plasma dimethylglycine) before and after
the load). Hemoglobin A1c did not correlate with either fast-
ing homocysteine or the post-methionine load increase in
homocysteine.













Figure 2 Multiple linear regression model for the post-methionine load increase in homocysteine. Top, in subjects with diabetes, bottom,
control subjects. Dependent variable: log(rise in plasma homocysteine). Independent variables: log(serum vitamin B12), log(post-methionine plasma
betaine) and log(baseline fasting homocysteine). Bars show the significance of the factors as t-values, negative for a negative relationship and positive
for a positive relationship; dashed lines p=0.05; dotted lines p=0.001. Pie graphs at the right show the proportion of variance (dark segment) explained
by regression: unexplained variance in grey.
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excretions
Data from all 51 subjects were combined and ranked on
betaine excretion. The factors affecting the post-methio-
nine load increase in homocysteine were identified in the
highest and lowest tertiles of betaine excretion (n= 17 in
each group) using best-subsets regression. In the highest
betaine excretion group the three significant predictors of
the increase in plasma homocysteine (expressed as log(rise
in homocysteine)) were fasting homocysteine (log trans-
formed), dimethylglycine excretion (log transformed) and
age, and in an explicit three-variable multiple linear regres-
sion model (Figure 3) these explained 81% of the variance
of the rise in homocysteine. Fasting homocysteine and
dimethylglycine excretion were significant (p< 0.001)
positive predictors whereas age was a negative predictor.
This three variable model was a poorer predictor in the
middle and lower tertile groups of betaine excretion
(Figure 3), explaining <50% of the variance, and in the
lower tertile there was a non-significant trend for
dimethylglycine excretion to be negatively associated with
the rise in homocysteine.
The differences between tertiles were also detected by
Pearson correlation coefficients between the rise in homo-
cysteine and fasting homocysteine (both log transformed)
and with dimethylglycine excretion (also log transformed).
In the upper tertile these were r=+0.70 (p=0.0018) and
+0.61 (p=0.009) respectively; in the lower tertile they were
r=+0.61 (p=0.010) and −0.41 (p=0.10). In the case of
dimethylglycine excretion the two correlation coefficients
were significantly different (p=0.0024). This was furtherevaluated by comparing the highest and lowest quartiles of
betaine excretion; in the highest quartile (n= 13) the corre-
sponding correlation between the rise in homocysteine
and dimethylglycine excretion was r=+0.61 (p=0.027)
and in the lowest quartile it was r=−0.62 (p=0.024); des-
pite the small numbers these are significantly different
(p=0.0013). In both quartiles the fasting homocysteine
was a positive predictor of the post-methionine rise in
homocysteine, r=+0.86, p=0.00002 in the highest quartile
and r=+0.65, p=0.017 in the lowest quartile.Discussion
Betaine is accumulated by most tissues as an osmolyte,
with tissue concentrations much higher than plasma
concentrations [3]. This tissue betaine is a major store of
methyl groups. Mobilizing betaine involves methylating
homocysteine to methionine, with the production of N,
N-dimethylglycine [9], and betaine is probably the main
regulator of non-fasting plasma homocysteine [9,12,24].
High urinary betaine loss is common in diabetes mellitus
[7,8,25], and may persist for years [26], potentially caus-
ing a betaine insufficiency that could be expected to have
complex consequences, affecting both the ability of cells
to maintain their volume and the supply of methyl
groups essential for normal metabolism [15,16,27]. Other
causes of deficiency could include a dietary insufficiency
of choline plus betaine. Betaine is either obtained from
the diet or by the mitochondrial oxidation of choline
[15,28], and defective conversion of choline to betaine is
another possible cause.
Lower tertile
















r2 = 0.27 
r2 = 0.44
Figure 3 Multiple linear regression model for the post-methionine load increase in homocysteine. Data on subjects with diabetes and
controls combined. Top, subjects in the highest tertile of betaine excretion and bottom in the lowest tertile of betaine excretion. Dependent variable:
log(rise in plasma homocysteine). Independent variables: log(baseline fasting homocysteine), log(dimethylglycine excretion as mmol dimethylglycine
per mole creatinine) and age (years). Bars show the significance of the factors as t-values, negative for a negative relationship and positive for a positive
relationship; dashed lines p=0.05; dotted lines p=0.001. Pie graphs at the right show the proportion of variance (dark segment) explained by
regression: unexplained variance in grey.
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diabetes and the control subjects is the greater variability
in plasma and (especially) urine betaine in the patients
with diabetes. This substantiates the impression pre-
sented visually in an earlier report [29], and could be
explained by a higher prevalence of both elevated and
decreased plasma and urine betaine in subjects with dia-
betes compared with the healthy population. Metabolites
related to betaine, such as dimethylglycine and homo-
cysteine, may also be more variable in diabetes, but a
larger study would be needed to confirm this. Superfi-
cially, it appears that in the subjects with diabetes,
plasma betaine is a stronger predictor of the post-
methionine load rise in homocysteine than it is in the
control subjects; however, this could be an artefact of the
greater variance (in diabetes) of all the factors in the re-
gression model. This possibility is supported by the fail-
ure of diabetes to appear as a significant factor when
regression models are generated using the population of
all subjects. Thus we confirm the findings of Holm et al.
[19] about the importance of betaine in determining the
post-methionine rise in homocysteine. Our finding thatfolate status failed to enter any of the regression models
is also in agreement with Holm et al. [19]. Despite the
possibility of bias being introduced by the age difference
between subjects with diabetes and the control subjects,
age was not a significant predictor of the post-methio-
nine rise in homocysteine in any model, even those
based on the combined population of all subjects.
This observational study cannot explain high and low
plasma betaine concentrations in diabetes. Plasma beta-
ine concentrations are normally tightly controlled [15,25]
and lower than intracellular concentrations [3]; efflux
from cells is both osmoregulated and hormonally con-
trolled. Compromise of this control could lead to ele-
vated plasma concentrations. Low plasma concentrations
may indicate a deficiency, for example as a result of urin-
ary loss, defective synthesis from choline or poor dietary
choices. High urinary excretion is presumably a renal
phenomenon [15] and may be associated with the role of
betaine as a renal osmolyte; low excretion is more likely
to reflect a genuine deficiency. Methyl metabolism, in-
cluding betaine metabolism, is disturbed in a rat model
of diabetes [27] and suggests other mechanistic models
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connect disturbed methyl metabolism with disturbed
osmoregulation.
The post-methionine load increase in homocysteine
has been proposed as a test for betaine insufficiency [15-
19]. This study supports this, though it was too small to
answer the question of whether elevated post-methionine
load responses were more common in diabetes, which
would imply a greater prevalence of betaine insufficiency
in diabetes. The subjects with diabetes and controls had
similar ranges of BMI and there were fewer subjects with
high betaine excretion in the diabetes group than we
have found in other studies. Thus the negative result is
inconclusive. However, the effect of betaine on this test
was confirmed. The load test is commonly regarded as
an independent risk factor for vascular disease [20,21]
though its value has been questioned [30]. Betaine sup-
plements have been shown to moderate the post-
methionine load increase in homocysteine in normal
subjects [19,31] and in renal failure patients [32]. The
relationship between dimethylglycine excretion and the
post-methionine load homocysteine response suggests
hypotheses that could be tested. Dimethylglycine is the
by-product of betaine-mediated homocysteine metabol-
ism and an increased production of it implies an
increased remethylation of homocysteine; the negative
correlation between the two in some subjects with low
betaine excretion suggests that this subgroup at least has
a primary betaine insufficiency (insufficient betaine to
moderate the rise in homocysteine), possibly because of
an inadequate intake of choline plus betaine, or a defect
in the mitochondrial oxidation of choline to betaine. The
low correlations in the group of subjects around the me-
dian betaine excretion are likely to reflect the lower var-
iances (in that group) of the variables.
This study does not address mechanisms for the elevated
loss of betaine in many subjects with diabetes. However,
betaine loss in at least some subjects with diabetes is asso-
ciated with poor glucose control, and the correlation with
urine glucose (rather than with plasma glucose) is consist-
ent with this being a renal effect. It could be informative to
investigate whether an increased production of sorbitol
(another renal osmolyte) from glucose is a contributing
mechanism, since sorbitol excretion is also elevated in dia-
betes and correlates with betaine excretion [7]. However,
this model would need to be reconciled with the observa-
tion in a sheep model that elevated glucose itself does not
directly cause an increased excretion of betaine [33].
Our results suggest that the supply of betaine may some-
times be limiting. Low plasma betaine has been associated
with an unfavourable risk profile in observational studies
[14,32], but conversely (in another observational study)
high plasma betaine has been associated with an increased
risk of vascular events [34]. Since betaine, a majorosmolyte, is well-known to be a protein-stabilizing com-
patible solute [35] and its intracellular concentrations are
orders of magnitude higher than those in circulation [3] it
is unlikely that an increase in circulating betaine can cause
damage, though it may indicate a pathological process, as
is seen in animal models when betaine-homocysteine
methyltransferase is absent or inhibited [24,36]. Another
possible pathological process is a failure of the tight con-
trol of betaine efflux from cells. Thus it is plausible that
both high and low plasma betaine concentrations may re-
flect pathological processes. However, betaine supplemen-
tation can increase plasma betaine, lower plasma
homocysteine, and is safe [37-39]. Betaine intake can be
also be increased by dietary choices [4,5]. We suggest that
urinary betaine excretion should be measured in patients
with diabetes to identify those with excessive betaine loss.
Such patients should be encouraged to increase their beta-
ine intakes with high betaine foods such as whole wheat
products [40,41], spinach and beets [4,5] or with betaine
supplements.
Conclusions
In diabetes high and low plasma betaine concentrations
are more common than in healthy subjects. Both high
and low urinary betaine excretions are also more preva-
lent in diabetes, with the high excretions being asso-
ciated with glucosuria. The availability of betaine affects
the response in the methionine load test but it is not
conclusively shown that this effect is more pronounced
in diabetes. It would be interesting to investigate whether
betaine supplementation of subjects with diabetes and
abnormal betaine markers alters their risk of developing
vascular disease.
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